osteoarthritis news from FierceBiotech

Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...

When Michael Novinski took over as CEO of Emisphere Technologies, he was acutely aware of just how unsuccessful the developer had been. For 20 years, he tells the Star-Ledger, Emisphere was never Read more...

Pfizer has once again demonstrated its zeal for biotech, inking a $250 million deal to in-license the worldwide rights Read more...

> The international relief agency Oxfam lays the decline in pharma's overall stock performance at the Read more...

> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis. Read more...

> Schering-Plough says that a mid-stage trial of its experimental oral thrombin receptor antagonist (TRA) demonstrated that the therapy was safe and did not increase major or minor bleeding in Read more...

Press Release: Genzyme Corporation's Hylastan Misses Goal in Arthritis Trial

Read more...

Galapagos has gained a €4.4 million equity investment from GlaxoSmithKline as the two companies expand an alliance on osteoarthritis. GSK will bring a drug discovery program against a selected GSK target into the alliance. Within this additional program, Galapagos will progress a disease-modifying drug toward completion of clinical Phase IIa, at which point GSK's global research and development organization will be responsible for the late-stage development, production and …

Read more...

> Seattle-based Omeros Corporation announced that the Stanley Medical Research Institute will provide up to $9 million in equity and grant funding toward the development of Omeros' proprietary drug candidate for the treatment of schizophrenia. The funding is expected to advance Omeros' schizophrenia program through the completion of Phase 1 clinical trials. …

Read more...

Press Release: FivePrime Enters Osteoarthritis and Pulmonary Fibrosis Collaboration With Centocor

Read more...